目的 探讨丹参酮Ⅱ_A磺酸钠注射液联合盐酸多奈哌齐片治疗轻度血管性认知障碍的临床疗效。方法 选取2015年9月—2017年9月重庆市人民医院康复医学科治疗的104例轻度血管性认知障碍患者作为研究对象，所有患者随机分为对照组和治疗组，每组各52例。对照组口服盐酸多奈哌齐片，5 mg/次，1次/d；治疗组在对照组治疗的基础上静脉滴注丹参酮Ⅱ_A磺酸钠注射液，40 mg丹参酮Ⅱ_A磺酸钠注射液加入5%葡萄糖注射液250 mL中，1次/d。两组患者疗程为2周，治疗4个疗程后观察其临床疗效。比较两组患者治疗前后的蒙特利尔认知评估量表（MoCA）评分、简易智力状态检查量表（MMSE）评分、日常生活能力量表（ADL）评分和炎性因子水平。结果 治疗后，治疗组总有效率为96.15%，显著高于对照组的76.92%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者MoCA、MMSE评分均显著升高，ADL评分显著降低，同组治疗前后比较差异具有统计学意义（P<0.05）；且治疗组治疗后MoCA、MMSE和ADL评分显著优于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者血清超敏C反应蛋白（hs-CRP）、白细胞介素-6（IL-6）和肿瘤坏死因子-α（TNF-α）水平均显著降低，同组治疗前后比较差异具有统计学意义（P<0.05）；且治疗组治疗后炎症因子水平显著低于对照组，两组比较差异具有统计学意义（P<0.05）。结论 丹参酮Ⅱ_A磺酸钠注射液联合盐酸多奈哌齐片治疗轻度血管性认知障碍的疗效显著，能够显著提高患者的认知能力和日常生活能力，改善血清炎性因子水平，且安全可靠，具有一定的临床推广应用价值。

Objective To investigate the clinical efficacy of Tanshinone Ⅱ_A Sulfonate Injection combined with Donepezil Hydrochloride Tablets in treatment of mild vascular cognitive impairment. Methods Patients (104 cases) with mild vascular cognitive impairment in Chongqing General Hospital from September 2015 to September 2017 were randomly divided into control and treatment groups, and each group had 52 cases. Patients in the control group were po administered with Donepezil Hydrochloride Tablets, 5 mg/time, once daily. Patients in the treatment group were iv administered with Tanshinone Ⅱ_A Sulfonate Injection on the basis of the control group, 40 mg added into 5% Glucose Injection 250 mL, once daily. Patients in two groups were treated for 2 weeks, and the clinical efficacy was observed after 4 courses of treatment. And the MoCA scores, MMSE scores, ADL scores, and serum inflammatory factors levels in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the treatment group was 96.15%, which was significantly higher than 76.92% in the control group, and there were differences between two groups (P<0.05). After treatment, the MoCA and MMSE scores in two groups were significantly increased, but ADL scores in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). After treatment, the MoCA, MMSE and ADL scores in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). After treatment, levels of hs-CRP, IL-6, and TNF-αin two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). After treatment, the serum levels of inflammatory factors in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). Conclusion Tanshinone Ⅱ_A Sulfonate Injection combined with Donepezil Hydrochloride Tablets has significant clinical efficacy in treatment of mild vascular cognitive impairment, can significantly improve the cognitive ability and daily living ability of patients, and improve the levels of serum inflammatory factors, and is safe and reliable, which has a certain clinical application value.